TABLE 3.

Patient-Level Data on Biologic Risk, Pre-HCT Therapy, Conditioning Regimen, and Outcome

UPN	Clinical Risk	Driver Mutation	Additional Mutation(s)	Cytogenetics	Methylation Status	Biologic Risk	Pre-HCT Chemo	Regimen	Outcome*
1	High	KRAS (p.G13D)	None	Normal	Low	Standard	None	Bu-Flu	Relapsed
2	Standard	KRAS (p.G13Y)	None	Normal	Low	Standard	None	Bu-Flu	Relapsed
3	High	RRAS (p.Q87L)	DNMT3A p.R882C	Monosomy 7	Low	High	Low-Dose	Bu-Flu	Relapsed
4	Standard	PTPN11 (p.E76K)	None	Normal	Intermediate	High	AML-Like	Bu-Flu	Disease-Free
5	High	PTPN11 (p.E76K)	None	Normal	Intermediate	High	None	Bu-Flu	Relapsed
6	High	NRAS (p.G12D)	None	t(3;5)	Intermediate	High	AML-Like	Bu-Flu	Disease-Free
7	High	PTPN11 (p.E76K)	CBL c.1227+4C>T	Normal	High	High	Low-Dose	Bu-Flu	Relapsed
8	High	PTPN11 (p.E76K)	NF1 (p.0splice_site)	Normal	High	High	None	Bu-Flu	Relapsed
9	High	PTPN11 (p.E76K)	None	Normal	Not Available	Standard	Low-Dose	Bu-Flu	TRM
10	High	KRAS (p.G13D)	None	Normal	Low	Standard	None	Bu-Cy-Mel	Relapsed
11	High	KRAS (p.G12V)	None	Normal	Low	Standard	Low-Dose	Bu-Cy-Mel	Disease-Free
12	Standard	NRAS (p.G13D)	None	Normal	Low	Standard	Low-Dose	Bu-Cy-Mel	Disease-Free
13	Standard	PTPN11 (p.E69K)	None	Normal	Low	Standard	Low-Dose	Bu-Cy-Mel	Disease-Free
14	Standard	PTPN11 (p.E76K)	None	Monosomy 7	Intermediate	High	Low-Dose	Bu-Cy-Mel	Disease-Free
15	High	PTPN11 (p.E76G)	JAK3 p.R657Q	Normal	High	High	None	Bu-Cy-Mel	Disease-Free

^*At time of last follow-up. Relapsed patients include patients with refractory disease and/or who were demonstrated to have JMML at time of count “recovery” from HCT.